Deutsche Bank AG analyst Falko Friedrichs conducted a comprehensive analysis of the Merck paper. Here are the findings noted.
Deutsche Bank Research raised the price target for Merck KGaA from 127 to 132 euros, but downgraded the shares from “Buy” to “Hold” due to a lack of potential. With his adjusted earnings estimate for the Darmstadt-based company for 2026, Falko Friedrichs is now 7 percent below the consensus after lowering it, and even up to 10 percent below the consensus for the following years. After the recent price recovery, he advises waiting for a better opportunity to get started.
Analysis and Stock Valuation: An examination of Merck stock at the time of analysis
FRANKFURT (dpa-AFX Analyzer) / editorial team finanzen.net
Publication of the original study: Date not specified in study / Time not specified in study / CET
First distribution of the original study: February 3rd, 2026 / 08:02 / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at http://web.dpa-afx.de/offenlegenspflicht/offenlegens_pflicht.html.
Selected leverage products on Merck
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Merck
The leverage must be between 2 and 20
Advertising
